Abstract
The study was carried out as an open-label, laboratory-blind, single-dose, randomized, two-period crossover, isotope efficacy study. Twenty-two patients with iron-deficiency anemia were enrolled in the study. The study consisted of two treatment phases of 15 days each, including blood sample measurements for Fe-59 activity. The two treatments were given orally. Treatment A was Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer) equivalent to 100 mg elemental iron given orally. Treatment B consisted of Fe-59 labeled IPC complex equivalent to 100 mg elemental iron and 500 mg tetracycline HCl (CAS 64-75-5) given orally. No differences between the two treatment groups with regard to the erythrocyte iron uptake were found, and thus IPC can be used with tetracycline, if necessary.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Anemia, Iron-Deficiency / drug therapy
-
Anemia, Iron-Deficiency / metabolism*
-
Anti-Bacterial Agents / blood
-
Anti-Bacterial Agents / pharmacokinetics*
-
Chemical Phenomena
-
Chemistry, Physical
-
Cross-Over Studies
-
Dietary Supplements
-
Drug Interactions
-
Erythrocyte Indices
-
Erythrocytes / metabolism
-
Female
-
Ferric Compounds / blood
-
Ferric Compounds / pharmacokinetics*
-
Ferric Compounds / therapeutic use
-
Ferritins / blood
-
Hemoglobins / metabolism
-
Humans
-
Iron / blood
-
Iron / pharmacokinetics*
-
Iron Chelating Agents / pharmacology
-
Iron Radioisotopes / pharmacokinetics
-
Male
-
Middle Aged
-
Prospective Studies
-
Quality Control
-
Sample Size
-
Single-Blind Method
-
Tetracycline / blood
-
Tetracycline / pharmacokinetics*
Substances
-
Anti-Bacterial Agents
-
Ferric Compounds
-
Hemoglobins
-
Iron Chelating Agents
-
Iron Radioisotopes
-
ferric hydroxide
-
Ferritins
-
Iron
-
Tetracycline
-
teferrol